Nephros (NEPH) Liabilities and Shareholders Equity (2016 - 2025)
Nephros has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $13.6 million for Q4 2025.
- Quarterly results put Liabilities and Shareholders Equity at $13.6 million for Q4 2025, up 21.69% from a year ago — trailing twelve months through Dec 2025 was $50.9 million (up 15.41% YoY), and the annual figure for FY2025 was $13.6 million, up 21.69%.
- Liabilities and Shareholders Equity for Q4 2025 was $13.6 million at Nephros, up from $13.2 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for NEPH hit a ceiling of $18.0 million in Q2 2021 and a floor of $10.4 million in Q2 2023.
- Median Liabilities and Shareholders Equity over the past 5 years was $11.8 million (2023), compared with a mean of $13.2 million.
- Biggest five-year swings in Liabilities and Shareholders Equity: tumbled 37.68% in 2022 and later increased 27.55% in 2025.
- Nephros' Liabilities and Shareholders Equity stood at $17.6 million in 2021, then crashed by 37.68% to $11.0 million in 2022, then grew by 7.84% to $11.9 million in 2023, then decreased by 5.49% to $11.2 million in 2024, then rose by 21.69% to $13.6 million in 2025.
- The last three reported values for Liabilities and Shareholders Equity were $13.6 million (Q4 2025), $13.2 million (Q3 2025), and $12.2 million (Q2 2025) per Business Quant data.